nach oben

Journal of Bone and Mineral Metabolism

Erschienen in:

18.11.2020 | Review Article

Sclerostin: from bench to bedside

verfasst von: Sakae Tanaka, Toshio Matsumoto

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Skeletal integrity is maintained by a meticulous balance between bone resorption and bone formation, and recent studies have revealed the essential role of canonical Wnt signaling pathways in maintaining skeletal homeostasis. The SOST gene, which encodes sclerostin, a member of Dan family glycoproteins, was originally identified as the gene responsible for two sclerosing bone dysplasias, sclerosteosis and van Buchem disease. Sclerostin is highly expressed by osteocytes, negatively regulates canonical Wnt signaling pathways by binding to low-density lipoprotein receptor-related protein (LRP) 5/6, and suppresses osteoblast differentiation and/or function. Romosozumab, a specific anti-sclerostin antibody, inhibits sclerostin-LRP5/6 interactions and indirectly activates canonical Wnt signaling pathways and bone formation. This review focuses on the mechanism of action of sclerostin and summarizes clinical studies that demonstrated the efficacy of romosozumab to increase bone mineral density and reduce osteoporotic fractures, as well as its cardiovascular safety.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference (2001). South Med J 94:569–573

Parfitt AM (1994) Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 55:273–286. https://doi.org/10.1002/jcb.240550303CrossRefPubMed

Tanaka S, Nakamura K, Takahasi N, Suda T (2005) Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system (in eng). Immunol Rev 208:30–49CrossRef

Tanaka S (2019) Molecular understanding of pharmacological treatment of osteoporosis. EFORT Open Rev 4:158–164. https://doi.org/10.1302/2058-5241.4.180018CrossRefPubMedPubMedCentral

Recker R, Lappe J, Davies KM, Heaney R (2004) Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 19:1628–1633. https://doi.org/10.1359/JBMR.040710CrossRefPubMed

Riggs BL, Parfitt AM (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177–184. https://doi.org/10.1359/JBMR.041114CrossRefPubMed

Truswell AS (1958) Osteopetrosis with syndactyly; a morphological variant of Albers-Schonberg’s disease. J Bone Joint Surg Br 40:209–218PubMed

Van Buchem FS, Hadders HN, Ubbens R (1955) An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol 44:109–120CrossRef

Balemans W, Van Den Ende J, Freire Paes-Alves A, Dikkers FG, Willems PJ, Vanhoenacker F, de Almeida-Melo N, Alves CF, Stratakis CA, Hill SC, Van Hul W (1999) Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21. Am J Hum Genet 64:1661–1669. https://doi.org/10.1086/302416CrossRefPubMedPubMedCentral

10.

Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577–589. https://doi.org/10.1086/318811CrossRefPubMedPubMedCentral

11.

Avsian-Kretchmer O, Hsueh AJW (2004) Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists (in English). Mol Endocrinol 18:1–12. https://doi.org/10.1210/me.2003-0227CrossRefPubMed

12.

Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N (2003) Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278:24113–24117. https://doi.org/10.1074/jbc.M301716200CrossRefPubMed

13.

Itasaki N, Jones CM, Mercurio S, Rowe A, Domingos PM, Smith JC, Krumlauf R (2003) Wise, a context-dependent activator and inhibitor of Wnt signalling. Development 130:4295–4305. https://doi.org/10.1242/dev.00674CrossRefPubMed

14.

Collette NM, Yee CS, Murugesh D, Sebastian A, Taher L, Gale NW, Economides AN, Harland RM, Loots GG (2013) Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner. Dev Biol 383:90–105. https://doi.org/10.1016/j.ydbio.2013.08.015CrossRefPubMedPubMedCentral

15.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883–19887. https://doi.org/10.1074/jbc.M413274200CrossRefPubMed

16.

Semenov M, Tamai K, He X (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280:26770–26775. https://doi.org/10.1074/jbc.M504308200CrossRefPubMed

17.

Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S et al (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513–523. https://doi.org/10.1016/s0092-8674(01)00571-2CrossRefPubMed

18.

Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513–1521. https://doi.org/10.1056/NEJMoa013444CrossRefPubMed

19.

Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M et al (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11–19. https://doi.org/10.1086/338450CrossRefPubMed

20.

Brance ML, Brun LR, Coccaro NM, Aravena A, Duan S, Mumm S, Whyte MP (2020) High bone mass from mutation of low-density lipoprotein receptor-related protein 6 (LRP6). Bone 141:115550. https://doi.org/10.1016/j.bone.2020.115550CrossRefPubMed

21.

Whyte MP, McAlister WH, Zhang F, Bijanki VN, Nenninger A, Gottesman GS, Lin EL, Huskey M, Duan S, Dahir K, Mumm S (2019) New explanation for autosomal dominant high bone mass: mutation of low-density lipoprotein receptor-related protein 6. Bone 127:228–243. https://doi.org/10.1016/j.bone.2019.05.003CrossRefPubMed

22.

Leupin O, Piters E, Halleux C, Hu S, Kramer I et al (2011) Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 286:19489–19500. https://doi.org/10.1074/jbc.M110.190330CrossRefPubMedPubMedCentral

23.

Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267–6276. https://doi.org/10.1093/emboj/cdg599CrossRefPubMedPubMedCentral

24.

Li X, Ominsky MS, Niu QT, Sun N, Daugherty B et al (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860–869. https://doi.org/10.1359/jbmr.080216CrossRefPubMed

25.

Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R (2006) Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 21:1738–1749. https://doi.org/10.1359/jbmr.060810CrossRefPubMed

26.

Semenov MV, He X (2006) LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 281:38276–38284. https://doi.org/10.1074/jbc.M609509200CrossRefPubMed

27.

Cui Y, Niziolek PJ, MacDonald BT, Zylstra CR, Alenina N et al (2011) Lrp5 functions in bone to regulate bone mass. Nat Med 17:684–691. https://doi.org/10.1038/nm.2388CrossRefPubMedPubMedCentral

28.

Holdsworth G, Roberts SJ, Ke HZ (2019) Novel actions of sclerostin on bone. J Mol Endocrinol 62:R167–R185. https://doi.org/10.1530/JME-18-0176CrossRefPubMed

29.

Yee CS, Manilay JO, Chang JC, Hum NR, Murugesh DK, Bajwa J, Mendez ME, Economides AE, Horan DJ, Robling AG, Loots GG (2018) Conditional deletion of Sost in MSC-derived lineages identifies specific cell-type contributions to bone mass and B-cell development. J Bone Miner Res 33:1748–1759. https://doi.org/10.1002/jbmr.3467CrossRefPubMed

30.

van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE (2010) Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 163:833–837. https://doi.org/10.1530/EJE-10-0699CrossRefPubMed

31.

Kramer I, Loots GG, Studer A, Keller H, Kneissel M (2010) Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178–189. https://doi.org/10.1359/jbmr.090730CrossRefPubMed

32.

Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866–5875. https://doi.org/10.1074/jbc.M705092200CrossRefPubMed

33.

Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, Bellido T (2012) Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone 50:209–217. https://doi.org/10.1016/j.bone.2011.10.025CrossRefPubMed

34.

Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH (2011) Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 26:2812–2822. https://doi.org/10.1002/jbmr.479CrossRefPubMed

35.

Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, Karaman M, Unal HU, Oguz Y, Sari S, Eyileten T, Goldsmith D, Vural A, Veisa G, Covic A, Yilmaz MI (2014) Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab 99:E1854–E1861. https://doi.org/10.1210/jc.2014-2042CrossRefPubMed

36.

Li X, Ominsky MS, Warmington KS, Morony S, Gong J et al (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578–588. https://doi.org/10.1359/jbmr.081206CrossRefPubMed

37.

Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ (2011) Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology 152:3312–3322. https://doi.org/10.1210/en.2011-0252CrossRefPubMed

38.

Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B et al (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25:948–959. https://doi.org/10.1002/jbmr.14CrossRefPubMed

39.

Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ (2014) Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology 155:4785–4797. https://doi.org/10.1210/en.2013-1905CrossRefPubMed

40.

Ominsky MS, Niu QT, Li C, Li X, Ke HZ (2014) Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res 29:1424–1430. https://doi.org/10.1002/jbmr.2152CrossRefPubMed

41.

Ominsky MS, Brown DL, Van G, Cordover D, Pacheco E, Frazier E, Cherepow L, Higgins-Garn M, Aguirre JI, Wronski TJ, Stolina M, Zhou L, Pyrah I, Boyce RW (2015) Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. Bone 81:380–391. https://doi.org/10.1016/j.bone.2015.08.007CrossRefPubMed

42.

Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P (2010) Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 25:2412–2418. https://doi.org/10.1002/jbmr.135CrossRefPubMed

43.

Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ (2011) Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26:1012–1021. https://doi.org/10.1002/jbmr.307CrossRefPubMed

44.

Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26. https://doi.org/10.1002/jbmr.173CrossRefPubMed

45.

Appelman-Dijkstra NM, Papapoulos SE (2016) Sclerostin inhibition in the management of osteoporosis. Calcif Tissue Int 98:370–380. https://doi.org/10.1007/s00223-016-0126-6CrossRefPubMedPubMedCentral

46.

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420. https://doi.org/10.1056/NEJMoa1305224CrossRefPubMed

47.

Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209–215. https://doi.org/10.1016/j.bone.2017.07.005CrossRefPubMed

48.

McClung MR, Brown JP, Diez-Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33:1397–1406. https://doi.org/10.1002/jbmr.3452CrossRefPubMed

49.

Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, Yan C, Yue S, Dinavahi RV, Libanati C, Grauer A (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30:2437–2448. https://doi.org/10.1007/s00198-019-05146-9CrossRefPubMedPubMedCentral

50.

Cosman F, Nieves JW, Dempster DW (2017) Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 32:198–202. https://doi.org/10.1002/jbmr.3051CrossRefPubMed

51.

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585–1594. https://doi.org/10.1016/S0140-6736(17)31613-6CrossRefPubMed

52.

Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Melby TE, Ruff VA (2018) Remodeling- and modeling-based bone formation with teriparatide versus denosumab: a longitudinal analysis from baseline to 3 months in the AVA study. J Bone Miner Res 33:298–306. https://doi.org/10.1002/jbmr.3309CrossRefPubMed

53.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543. https://doi.org/10.1056/NEJMoa1607948CrossRefPubMed

54.

Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C, Milmont CE, Meisner PD, Libanati C, Grauer A (2018) Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res 33:1407–1416. https://doi.org/10.1002/jbmr.3439CrossRefPubMed

55.

Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 34:419–428. https://doi.org/10.1002/jbmr.3622CrossRefPubMed

56.

Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103:3183–3193. https://doi.org/10.1210/jc.2017-02163CrossRefPubMed

57.

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427. https://doi.org/10.1056/NEJMoa1708322CrossRefPubMed

58.

Asadipooya K, Weinstock A (2019) Cardiovascular outcomes of romosozumab and protective role of alendronate. Arterioscler Thromb Vasc Biol 39:1343–1350. https://doi.org/10.1161/ATVBAHA.119.312371CrossRefPubMed

59.

Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Cheung TT, Chan EW, Kung AW, Wong IC, Cheung CL (2018) Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 33:1422–1434. https://doi.org/10.1002/jbmr.3448CrossRefPubMed

60.

Takashima N, Arima H, Kita Y, Fujii T, Miyamatsu N, Komori M, Sugimoto Y, Nagata S, Miura K, Nozaki K (2017) Incidence, management and short-term outcome of stroke in a general population of 1.4 million Japanese- Shiga stroke registry. Circ J 81:1636–1646. https://doi.org/10.1253/circj.CJ-17-0177CrossRefPubMed

61.

Rumana N, Kita Y, Turin TC, Murakami Y, Sugihara H, Morita Y, Tomioka N, Okayama A, Nakamura Y, Abbott RD, Ueshima H (2008) Trend of increase in the incidence of acute myocardial infarction in a Japanese population: Takashima AMI Registry, 1990–2001. Am J Epidemiol 167:1358–1364. https://doi.org/10.1093/aje/kwn064CrossRefPubMed

Titel: Sclerostin: from bench to bedside
verfasst von: Sakae Tanaka
Toshio Matsumoto
Publikationsdatum: 18.11.2020
Verlag: Springer Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 3/2021
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-020-01176-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Sclerostin: from bench to bedside

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Incidence rate of vitamin D deficiency and FGF23 levels in 12- to 13-year-old adolescents in Japan

Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw

Teriparatide and exercise improve bone, skeletal muscle, and fat parameters in ovariectomized and tail-suspended rats

Association between movement control during one-leg standing and femoral BMD in patients with hip fractures

Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study

Retraction Note to: Effect of alendronate on bone mineral density and bone turnovermarkers in post-gastrectomy osteoporotic patients

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin